BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) have been given a consensus recommendation of “Moderate Buy” by the fifteen brokerages that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and thirteen have given a buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $378.4286.

A number of brokerages have issued reports on ONC. Jefferies Financial Group reaffirmed a “buy” rating and issued a $420.00 target price on shares of BeOne Medicines in a report on Monday, November 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BeOne Medicines in a report on Wednesday. Citizens Jmp boosted their target price on BeOne Medicines from $348.00 to $396.00 and gave the stock a “market outperform” rating in a research report on Friday, November 7th. Truist Financial set a $400.00 target price on BeOne Medicines in a report on Monday, November 24th. Finally, JPMorgan Chase & Co. lifted their price target on BeOne Medicines from $345.00 to $385.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 8th.

BeOne Medicines Stock Performance

Shares of ONC opened at $339.32 on Friday. The company has a quick ratio of 2.17, a current ratio of 2.39 and a debt-to-equity ratio of 0.03. BeOne Medicines has a 52-week low of $196.45 and a 52-week high of $385.22. The company has a 50-day simple moving average of $328.39 and a 200-day simple moving average of $319.54. The company has a market capitalization of $37.21 billion, a PE ratio of 665.33 and a beta of 0.47.

Insider Buying and Selling at BeOne Medicines

In related news, SVP Chan Henry Lee sold 996 shares of the company’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $349.17, for a total value of $347,773.32. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Xiaobin Wu sold 10,000 shares of the stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $356.02, for a total value of $3,560,200.00. Following the sale, the chief operating officer owned 6,009 shares in the company, valued at approximately $2,139,324.18. This trade represents a 62.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 128,610 shares of company stock worth $41,114,068. 6.62% of the stock is currently owned by insiders.

Institutional Trading of BeOne Medicines

Institutional investors and hedge funds have recently made changes to their positions in the stock. Anchor Investment Management LLC acquired a new position in BeOne Medicines in the 2nd quarter valued at about $26,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of BeOne Medicines during the second quarter worth about $28,000. Daiwa Securities Group Inc. purchased a new position in shares of BeOne Medicines during the second quarter valued at approximately $35,000. Farther Finance Advisors LLC purchased a new stake in BeOne Medicines in the 2nd quarter worth approximately $39,000. Finally, Signaturefd LLC acquired a new position in BeOne Medicines in the 2nd quarter valued at $49,000. 48.55% of the stock is currently owned by hedge funds and other institutional investors.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.